ZEALAND PHARMA A/S (22Z.DE) Stock Fundamental Analysis
Europe - FRA:22Z - DK0060257814 - Common Stock
67.54 EUR
+2.54 (+3.91%)
Taking everything into account, 22Z scores 6 out of 10 in our fundamental rating. 22Z was compared to 76 industry peers in the Biotechnology industry. 22Z has an excellent financial health rating, but there are some minor concerns on its profitability. 22Z is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 22Z was profitable.
In the past year 22Z had a positive cash flow from operations.
In the past 5 years 22Z always reported negative net income.
In the past 5 years 22Z always reported negative operating cash flow.
1.2 Ratios
22Z has a better Return On Assets (38.89%) than 97.37% of its industry peers.
The Return On Equity of 22Z (42.80%) is better than 98.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 32.36%, 22Z belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| ROIC | 32.36% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
22Z's Profit Margin of 73.34% is amongst the best of the industry. 22Z outperforms 98.68% of its industry peers.
With an excellent Operating Margin value of 81.00%, 22Z belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
The Gross Margin of 22Z (100.06%) is better than 97.37% of its industry peers.
22Z's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 81% | ||
| PM (TTM) | 73.34% | ||
| GM | 100.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 22Z is creating value.
The number of shares outstanding for 22Z has been increased compared to 1 year ago.
22Z has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 22Z has been reduced compared to a year ago.
2.2 Solvency
22Z has an Altman-Z score of 12.00. This indicates that 22Z is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 22Z (12.00) is better than 88.16% of its industry peers.
The Debt to FCF ratio of 22Z is 0.05, which is an excellent value as it means it would take 22Z, only 0.05 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.05, 22Z belongs to the best of the industry, outperforming 97.37% of the companies in the same industry.
22Z has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 22Z (0.02) is better than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 12 |
ROIC/WACC4.64
WACC6.97%
2.3 Liquidity
A Current Ratio of 15.09 indicates that 22Z has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.09, 22Z belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
22Z has a Quick Ratio of 15.08. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 15.08, 22Z belongs to the top of the industry, outperforming 96.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 921.54% over the past year.
Looking at the last year, 22Z shows a very strong growth in Revenue. The Revenue has grown by 2375.69%.
Measured over the past years, 22Z shows a quite strong growth in Revenue. The Revenue has been growing by 8.69% on average per year.
EPS 1Y (TTM)921.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2404.28%
Revenue 1Y (TTM)2375.69%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%26527.65%
3.2 Future
Based on estimates for the next years, 22Z will show a decrease in Earnings Per Share. The EPS will decrease by -2.54% on average per year.
Based on estimates for the next years, 22Z will show a very strong growth in Revenue. The Revenue will grow by 123.26% on average per year.
EPS Next Y638.53%
EPS Next 2Y82.04%
EPS Next 3Y9.07%
EPS Next 5Y-2.54%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y123.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 5.31, which indicates a rather cheap valuation of 22Z.
Compared to the rest of the industry, the Price/Earnings ratio of 22Z indicates a rather cheap valuation: 22Z is cheaper than 94.74% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of 22Z to the average of the S&P500 Index (26.03), we can say 22Z is valued rather cheaply.
A Price/Forward Earnings ratio of 23.59 indicates a rather expensive valuation of 22Z.
22Z's Price/Forward Earnings ratio is rather cheap when compared to the industry. 22Z is cheaper than 84.21% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 22Z to the average of the S&P500 Index (22.27), we can say 22Z is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.31 | ||
| Fwd PE | 23.59 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, 22Z is valued cheaply inside the industry as 98.68% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.09 | ||
| EV/EBITDA | -0.31 |
4.3 Compensation for Growth
22Z's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y82.04%
EPS Next 3Y9.07%
5. Dividend
5.1 Amount
No dividends for 22Z!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:22Z (11/4/2025, 7:00:00 PM)
67.54
+2.54 (+3.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners48.71%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap3.11B
Revenue(TTM)9.11B
Net Income(TTM)6.68B
Analysts85
Price Target107.77 (59.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-314.33%
Min EPS beat(2)-623.11%
Max EPS beat(2)-5.54%
EPS beat(4)1
Avg EPS beat(4)-152.35%
Min EPS beat(4)-623.11%
Max EPS beat(4)23.23%
EPS beat(8)3
Avg EPS beat(8)-58.82%
EPS beat(12)5
Avg EPS beat(12)-38.11%
EPS beat(16)7
Avg EPS beat(16)-28.16%
Revenue beat(2)0
Avg Revenue beat(2)-39.07%
Min Revenue beat(2)-74.61%
Max Revenue beat(2)-3.53%
Revenue beat(4)0
Avg Revenue beat(4)-58.45%
Min Revenue beat(4)-92.1%
Max Revenue beat(4)-3.53%
Revenue beat(8)4
Avg Revenue beat(8)65%
Revenue beat(12)6
Avg Revenue beat(12)54.69%
Revenue beat(16)6
Avg Revenue beat(16)27.38%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-5.05%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.31 | ||
| Fwd PE | 23.59 | ||
| P/S | 2.55 | ||
| P/FCF | 3.09 | ||
| P/OCF | 3.08 | ||
| P/B | 1.49 | ||
| P/tB | 1.49 | ||
| EV/EBITDA | -0.31 |
EPS(TTM)12.72
EY18.83%
EPS(NY)2.86
Fwd EY4.24%
FCF(TTM)21.85
FCFY32.35%
OCF(TTM)21.91
OCFY32.43%
SpS26.46
BVpS45.33
TBVpS45.29
PEG (NY)0.01
PEG (5Y)N/A
Graham Number113.9
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| ROCE | 45.97% | ||
| ROIC | 32.36% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 81% | ||
| PM (TTM) | 73.34% | ||
| GM | 100.06% | ||
| FCFM | 82.59% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
F-Score8
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 77.22% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 405.42 | ||
| Cash Conversion | 101.88% | ||
| Profit Quality | 112.62% | ||
| Current Ratio | 15.09 | ||
| Quick Ratio | 15.08 | ||
| Altman-Z | 12 |
F-Score8
WACC6.97%
ROIC/WACC4.64
Cap/Depr(3y)51.82%
Cap/Depr(5y)53.82%
Cap/Sales(3y)13.05%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)921.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2404.28%
EPS Next Y638.53%
EPS Next 2Y82.04%
EPS Next 3Y9.07%
EPS Next 5Y-2.54%
Revenue 1Y (TTM)2375.69%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%26527.65%
Revenue Next Year11614.8%
Revenue Next 2Y668.41%
Revenue Next 3Y251.45%
Revenue Next 5Y123.26%
EBIT growth 1Y1123.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year744.74%
EBIT Next 3Y22.1%
EBIT Next 5Y15.77%
FCF growth 1Y1062.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1078.6%
OCF growth 3YN/A
OCF growth 5YN/A
ZEALAND PHARMA A/S / 22Z.DE FAQ
What is the ChartMill fundamental rating of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE.
What is the valuation status of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to ZEALAND PHARMA A/S (22Z.DE). This can be considered as Fairly Valued.
What is the profitability of 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) has a profitability rating of 5 / 10.
What is the valuation of ZEALAND PHARMA A/S based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ZEALAND PHARMA A/S (22Z.DE) is 5.31 and the Price/Book (PB) ratio is 1.49.
What is the financial health of ZEALAND PHARMA A/S (22Z.DE) stock?
The financial health rating of ZEALAND PHARMA A/S (22Z.DE) is 9 / 10.